YQ23 Study in Patients With Critical Limb Ischaemia
Phase 1
Terminated
- Conditions
- Critical Limb Ischemia
- Interventions
- Biological: Matching placeboBiological: YQ23
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- New Beta Innovation Limited
- Target Recruit Count
- 5
- Registration Number
- NCT04792008
- Locations
- ππ°
Queen Mary Hospital, Hong Kong, Hong Kong
ππ°Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong
A Safety Study of YQ23 in Advanced Solid Tumors Patients
Phase 1
Terminated
- Conditions
- Advanced Solid Tumor
- Interventions
- Combination Product: PembrolizumabBiological: YQ23
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- New Beta Innovation Limited
- Target Recruit Count
- 3
- Registration Number
- NCT04513067
- Locations
- ππ°
The University of Hong Kong Phase I Clinical Trials Centre, Hong Kong, Hong Kong
First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Biological: YQ23Biological: Matching Placebo
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- New Beta Innovation Limited
- Target Recruit Count
- 58
- Registration Number
- NCT03802292
- Locations
- π¬π§
Covance CRU Limited, Leeds, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath